Keith Katkin served as the chief executive officer and as a member of the board of directors of Urovant Sciences Ltd, a public biopharmaceutical company, from September 2017 until March 2020. Prior to Urovant, Mr. Katkin served as the president and chief executive officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2007 to 2016, where he led the growth and ultimate sale of Avanir to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion. Prior to joining Avanir, Mr. Katkin served as the vice president, commercial development for Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson & Johnson.
Mr. Katkin currently serves on the boards of Eledon Pharmaceuticals, Inc. (chairman), Rigel Pharmaceuticals, Inc., and Syndax Pharmaceuticals, each of which is a publicly traded company, and as an adviser to the board of directors at Urovant.
Mr. Katkin has an MBA from the Anderson School at UCLA and a Bachelor of Science in Business and Accounting from Indiana University. Mr. Katkin is also a licensed Certified Public Accountant.
What is Keith Katkin's net worth?
The estimated net worth of Keith Katkin is at least $1.04 million as of May 23rd, 2025. Katkin owns 86,431 shares of Emergent Biosolutions stock worth more than $1,040,889 as of December 5th. This net worth evaluation does not reflect any other investments that Katkin may own. Learn More about Keith Katkin's net worth.
How do I contact Keith Katkin?
Has Keith Katkin been buying or selling shares of Emergent Biosolutions?
Keith Katkin has not been actively trading shares of Emergent Biosolutions during the last ninety days. Most recently, Keith Katkin sold 7,844 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $6.30, for a transaction totalling $49,417.20. Following the completion of the sale, the director now directly owns 86,431 shares of the company's stock, valued at $544,515.30. Learn More on Keith Katkin's trading history.
Who are Emergent Biosolutions' active insiders?
Are insiders buying or selling shares of Emergent Biosolutions?
During the last twelve months, insiders at the biopharmaceutical company sold shares 5 times. They sold a total of 88,382 shares worth more than $690,250.62. The most recent insider tranaction occured on October, 7th when EVP Coleen Glessner sold 30,608 shares worth more than $306,080.00. Insiders at Emergent Biosolutions own 1.2% of the company.
Learn More about insider trades at Emergent Biosolutions. Information on this page was last updated on 10/7/2025.
